Serum biomarker CD163 predicts overall survival in patients with pancreatic ductal adenocarcinoma
Abstract. The serum soluble CD163 (sCD163) is elevated in patients with inflammatory disease and several types of cancer. However, the prognostic value of serum sCD163 in pancreatic ductal adenocarcinoma (PDAC) has not yet been investigated. In this study, serum level of sCD163 was measured by using...
| Autori principali: | , , , , , |
|---|---|
| Natura: | Articolo |
| Lingua: | English |
| Pubblicazione: |
Wolters Kluwer Health/LWW
2020-09-01
|
| Serie: | Journal of Pancreatology |
| Accesso online: | http://journals.lww.com/10.1097/JP9.0000000000000055 |